Answers are grounded in this paper and cite their sources.
It has been possible to verify that the application of biomarkers could help detect prostate cancer (PCa) patients with a higher risk of poorer evolution. The Prostate Health Index shows an ability to identify 95-100 for every 100 patients suffering from clinically significant PCa who take the test, preventing unnecessary biopsies in 14-33% of men without PCa or insignificant PCa.
No takes yet. Share an insight, caveat, or question.
Pino‐Sedeño et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: